Julen Oyarzábal - Concepedia

Author

Julen Oyarzábal

Also Known As

J Oyarzabal, J. C. Oyarzabal, J. OYARZABAL, J. Oyarzabal, J. Oyarzábal, J.C. Oyarzábal, Juan José Lasarte, Julen Oyarzabal, Julen Oyarzábal, Oyarzabal, J.

166

Publications

6.8K

Citations

H-Index

142

Concepts

All Affiliations

Universidad de Navarra Spanish National Cancer Research Centre Navarre Institute of Health Research Clinica Universidad de Navarra Universitat de Barcelona

About

Julen Oyarzábal is an author at Universidad de Navarra specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	44	2.8K
2	Natural Sciences	19	25	804
3	Engineering	8	8	701
4	Social Sciences	3	3	319
5	Health Sciences	1	1	46

Julen Oyarzábal

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations Luis Toledo, Matilde Murga, Rafal Zur, Nature Structural & Molecular Biology Cancer-associated MutationsEngineeringSynthetic Lethal PropertiesSomatic VariantOncogenic Agent	2011	458
The CHEMDNER corpus of chemicals and drugs and its annotation principles Martin Krallinger, Obdulia Rabal, Florian Leitner, Journal of Cheminformatics	2015	415
CHEMDNER: The drugs and chemical names extraction challenge Martin Krallinger, Florian Leitner, Obdulia Rabal, Journal of Cheminformatics	2015	267
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect Ester Lara, Antonello Mai, Vincenzo Calvanese, Oncogene OncologyMedicinePathologySirtuin InhibitorImmune Checkpoint Inhibitor	2008	260
Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors Eva Martínez‐Pinilla, Katia Varani, Irene Reyes‐Resina, Frontiers in Pharmacology	2017	192
Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD Carolina García, Ana Ricobaraza, María Pascual‐Lucas, Neuropharmacology Neurodegenerative DiseasesAlzheimer's DiseaseBlood–brain BarrierNeurophysiologyMedicine	2012	184
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression Cristina Segovia, Edurne San José‐Eneriz, Ester Munera-Maravilla, Nature Medicine Cancer ImmunosurveillanceGenitourinary CancerImmunologyCancer GenomicsImmune Checkpoint Inhibitor	2019	184
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies Edurne San José‐Eneriz, Xabier Agirre, Obdulia Rabal, Nature Communications Hematological MalignancyReversible Chemical ProbesEpigenetic DrugsNovel TherapyChemical Series	2017	161
Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease Carmen Roncal, E. Martínez-Aguilar, Josune Orbe, Scientific Reports	2019	154
The AhpC and AhpD Antioxidant Defense System of Mycobacterium tuberculosis Patrick J. Hillas, Federico Soto del Alba, Julen Oyarzábal, Journal of Biological Chemistry	2000	139

Page 1